Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

121. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition Full Text available with Trip Pro

Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition The expected duration of menopausal vasomotor symptoms (VMS) is important to women making decisions about possible treatments.To determine total duration of frequent VMS (≥ 6 days in the previous 2 weeks) (hereafter total VMS duration) during the menopausal transition, to quantify how long frequent VMS persist after the final menstrual period (FMP) (hereafter post-FMP persistence), and to identify risk factors for longer (...) total VMS duration and longer post-FMP persistence.The Study of Women's Health Across the Nation (SWAN) is a multiracial/multiethnic observational study of the menopausal transition among 3302 women enrolled at 7 US sites. From February 1996 through April 2013, women completed a median of 13 visits. Analyses included 1449 women with frequent VMS.Total VMS duration (in years) (hot flashes or night sweats) and post-FMP persistence (in years) into postmenopause.The median total VMS duration was 7.4

2015 EvidenceUpdates

122. Dehydroepiandrosterone for the Treatment of Menopausal or Andropausal Symptoms

Dehydroepiandrosterone for the Treatment of Menopausal or Andropausal Symptoms Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) of Menopausal or Andropausal Symptoms: Clinical Effectiveness and Safety DATE: 25 February 2015 RESEARCH QUESTION What is the clinical effectiveness and safety of dehydroepiandosterone (DHEA) for the treatment of menopausal or andropausal symptoms? KEY FINDINGS Two systematic reviews, two randomized controlled trials, and one non-randomized study were identified regarding the clinical effectiveness and safety of DHEA for the treatment of menopausal symptoms; no evidence was identified regarding DHEA

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

123. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial Full Text available with Trip Pro

The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial To investigate the effectiveness of exercise as treatment for vasomotor menopausal symptoms.Three-group randomised controlled trial, two exercise interventions and a control group.Primary Care, West Midlands UK.Perimenopausal and postmenopausal women experiencing at least five hot flushes/night sweats per day and not taken MHT in previous 3 months were recruited from 23 general (...) practices.Participants in both exercise interventions groups were offered two face-to-face consultations with a physical activity facilitator to support engagement in regular exercise. In addition, one exercise group received a menopause-specific information DVD and written materials to encourage regular exercise and the other exercise group was offered the opportunity to attend exercise social support groups in their communities. Interventions lasted 6 months.The primary outcome was frequency of hot flushes/night

2015 EvidenceUpdates Controlled trial quality: uncertain

124. Menopausal Symptoms: Comparative Effectiveness of Therapies

Menopausal Symptoms: Comparative Effectiveness of Therapies Menopausal Symptoms: Comparative Effectiveness of Therapies Comparative Effectiveness Review Number 147Comparative Effectiveness Review Number 147 Menopausal Symptoms: Comparative Effectiveness of Therapies Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10058-I Prepared by: Blue Cross and Blue Shield (...) presented in this report. Suggested citation: Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C, Ziegler KM, Aronson N. Menopausal Symptoms: Comparative Effectiveness of Therapies. Comparative Effectiveness Review No. 147. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007- 10058-I.) AHRQ Publication No. 15-EHC005-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2015

2015 Effective Health Care Program (AHRQ)

125. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Copyright @ 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Abstract Objective: To update and expand The North American Menopause Society’s evidence-based position (...) on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. Methods: NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees. Results: Nonhormonal management of VMS

2015 The North American Menopause Society

126. Treatment of Symptoms of the Menopause

Treatment of Symptoms of the Menopause '); '); Treatment of the Symptoms of Menopause Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Full Guideline: JCEM | November 2015 Cynthia A. Stuenkel (chair), Susan R. Davis, Anne Gompel, Mary Ann Lumsden, M. Hassan Murad, JoAnn V. Pinkerton, and Richard J. Santen The 2015 guideline addresses: General evaluation and health considerations for menopausal women Evaluating hormone (...) replacement options and associated risks Monitoring patients during hormone therapies Treating genitourinary syndrome Resources | ENDO 2015 | Guideline Central | Hormone Health Network | Endocrine Society Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline | ENDO 2015 Essential Points The Endocrine Society recommends that women with a uterus who decide to undergo menopausal hormone therapy with estrogen and progestogen be informed about risks and benefits, including

2015 The Endocrine Society

127. Have we best addressed women's midlife sleep quality? A systematic review on the effects of low dose hormone therapy and route of administration on self-reported sleep outcomes in menopausal women

Have we best addressed women's midlife sleep quality? A systematic review on the effects of low dose hormone therapy and route of administration on self-reported sleep outcomes in menopausal women Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2015 PROSPERO

128. Prevention of chemotherapy-induced early menopause in breast cancer: systematic review and meta-analysis

Prevention of chemotherapy-induced early menopause in breast cancer: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2015 PROSPERO

129. Systematic review on the comparison of effectiveness between Denosumab and Bisphosphonates in post-menopausal osteoporosis

Systematic review on the comparison of effectiveness between Denosumab and Bisphosphonates in post-menopausal osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

130. Decision aids for the management of menopausal symptoms [Cochrane Protocol]

Decision aids for the management of menopausal symptoms [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2015 PROSPERO

131. Dehydroepiandrosterone for menopausal women [Cochrane Protocol]

Dehydroepiandrosterone for menopausal women [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2015 PROSPERO

132. Does bone mineral density influence periodontal attachment level in post-menopausal women? A systematic review

Does bone mineral density influence periodontal attachment level in post-menopausal women? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

133. Incidence and risk of depression in menopausal women with vasomotor symptoms: a systematic review and meta-analysis of longitudinal cohort studies

Incidence and risk of depression in menopausal women with vasomotor symptoms: a systematic review and meta-analysis of longitudinal cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO

134. Menopause: diagnosis and management

Menopause: diagnosis and management Menopause: diagnosis and management Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Menopause: diagnosis and management (NG23) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Individualised care 5 1.2 Diagnosis

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

135. A systematic review and meta-analysis of the association between moderate-vigorous recreational physical activity and breast cancer risk, stratified by menopausal status

A systematic review and meta-analysis of the association between moderate-vigorous recreational physical activity and breast cancer risk, stratified by menopausal status Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2015 PROSPERO

136. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review Full Text available with Trip Pro

Vaginal estrogen for genitourinary syndrome of menopause: a systematic review To comprehensively review and critically assess the literature on vaginal estrogen and its alternatives for women with genitourinary syndrome of menopause and to provide clinical practice guidelines.MEDLINE and Cochrane databases were searched from inception to April 2013. We included randomized controlled trials and prospective comparative studies. Interventions and comparators included all commercially available

2015 EvidenceUpdates

137. Exercise for vasomotor menopausal symptoms. Full Text available with Trip Pro

Exercise for vasomotor menopausal symptoms. Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausal symptoms; hot flushes are the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by hormone therapy (HT), but a marked global decline in its use has resulted from concerns about the risks and benefits of HT. Consequently, many women are seeking alternatives. As large numbers of women are choosing not to take HT (...) , it is increasingly important to identify evidence-based lifestyle modifications that have the potential to reduce vasomotor menopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotor symptoms in symptomatic perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility Group Specialised Trials Register

2014 Cochrane

138. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole

Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole NIHR HSC Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Breast Neoplasms; Female; Humans Language Published English

2014 Health Technology Assessment (HTA) Database.

139. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) en mujeres post menopáusicas. [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 308. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage policy related aspect for denosumab versus bisphosphonates in decreasing the risk of fractures due to post-menopausal osteoporosis. Authors' conclusions

2014 Health Technology Assessment (HTA) Database.

140. Menopause Chapter 8: Prescription Therapies

Menopause Chapter 8: Prescription Therapies Chapter 8: Prescription Therapies | | | | Chapter 8: Prescription Therapies > > > CONTRACEPTIVES Key Points Despite a decline in fertility, women of older reproductive age who do not wish to conceive should use effective contraception until 1 year after the final menstrual period. Long-acting reversible contraceptive methods, which include the copper intrauterine device (IUD), the two levonorgestrel intrauterine systems, and the etonogestrel subdermal (...) with a uterus. Systemic HT and low-dose vaginal ET are very effective treatments for moderate to severe symptoms of vulvar and vaginal atrophy (vaginal dryness, dyspareunia, and atrophic vaginitis). The estrogen agonist/antagonist ospemifene is a new oral agent approved for this indication. Recommendations for Clinical Care The lowest dose of HT should be used for the shortest duration needed to manage menopausal symptoms. Individualization is important in the decision to use HT and should incorporate

2014 The North American Menopause Society